Spero Therapeutics (SPRO) to Release Quarterly Earnings on Wednesday

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) will announce its earnings results after the market closes on Wednesday, May 15th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last posted its earnings results on Wednesday, March 13th. The company reported $0.96 earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $1.14. Spero Therapeutics had a net margin of 21.98% and a return on equity of 38.54%. The firm had revenue of $73.52 million for the quarter, compared to the consensus estimate of $19.40 million. On average, analysts expect Spero Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Spero Therapeutics Price Performance

Shares of Spero Therapeutics stock traded up $0.02 during trading hours on Thursday, reaching $1.69. The company's stock had a trading volume of 112,483 shares, compared to its average volume of 278,372. The firm has a 50 day moving average price of $1.64 and a 200-day moving average price of $1.44. Spero Therapeutics has a one year low of $0.99 and a one year high of $1.98. The stock has a market cap of $91.08 million, a P/E ratio of 4.02 and a beta of 0.62.

Analyst Ratings Changes

SPRO has been the topic of a number of research reports. HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Spero Therapeutics in a report on Monday, March 18th. Cantor Fitzgerald restated an "overweight" rating on shares of Spero Therapeutics in a report on Thursday, April 4th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.